About VENUS MEDTECH-B Company

Hangzhou Qiming Medical Devices Co., Ltd. (“Qiming Medical”) is the leading enterprise in the field of minimally invasive cardiac valve interventional treatment in China, and is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. Qiming Medical was founded in 2009 and is located in Hangzhou National High-tech Industrial Development Zone (Binjiang). In 2014, the company won the national biomedical industry championship with the “Novel Biological Cardiac Aortic Valve Project” and excelled in this field. The company has four “China's No. 1” titles: the first to begin and complete clinical research registered with the NMPA in China, the first cardiovascular device to receive support from the NMPA Innovation Channel, the first Chinese heart valve device to enter Europe for clinical implantation in humans, and the first company to be approved to establish a heart valve research institute in China. On December 10, 2019, the company was successfully listed on the main board of the Hong Kong Stock Exchange under the stock code 02500. At present, Qiming Medical has established a comprehensive structural heart disease overall solution, covering a complete pipeline of heart valve diseases such as aortic valve, pulmonary valve valve, mitral valve, and tricuspid valves, hypertrophic cardiomyopathy, hypertensive renal artery desympathetic ablation, and surgical support products. By the end of August 2021, Qiming Medical had a total of 507 patents and patent applications, including 209 authorized invention patents. The main countries and regions covered include China, the United States, Europe, Japan, Canada, Russia, India, Brazil, etc. As a local innovative enterprise, Qiming Medical has won many awards and honors, including the 12th and 13th Five-Year National Science and Technology Support Program awards assessed by China's Ministry of Science and Technology, the second batch of specialized and innovative “little giant” enterprises, the China Outstanding Patent Award, outstanding domestic medical equipment products, and national high-tech enterprises. In the future, Qiming Medical will focus on developing new materials, bionics, influencing fusion technology and the direction of digital sensing, continuously updating and iterating, and promoting innovation to meet the needs of a wide range of doctors and patients. The company will not only be a leader in the field of heart valves, but also expect the Qiming medical model to provide a strong reference for the development of China's innovative medical industry. Innovation leads the future, and Qiming Medical will continue to work on the development and marketization of innovative structural heart disease medical devices to accelerate innovation in China and benefit the world.